Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PDXK | O00764 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | TKT | P29401 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27911502 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL12186160 | 0.79 | LMNA (0.42) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL15211577 | 0.78 | PDXK (0.46) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL479344 | 0.78 | LMNA (0.61) | KDM4EALDH1A1LMNATKT | |
| SCHEMBL23094501 | 0.78 | LMNA (0.50) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL21713021 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL11325842 | 0.77 | LMNA (0.41) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL14677401 | 0.77 | LMNA (0.46) | KDM4EALDH1A1LMNATKT | |
| SCHEMBL2118802 | 0.77 | LMNA (0.41) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL6520994 | 0.77 | LMNA (0.59) | KDM4EALDH1A1LMNATKT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197337-A1 | CONVERSION OF TRIACETIC ACID LACTONE TO POTASSIUM SORBATE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-06-19 | — | — | US | claimed |
| WO-2025128424-A1 | CONVERSION OF TRIACETIC ACID LACTONE TO POTASSIUM SORBATE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-06-19 | — | — | WO | claimed |
| CN-115109761-A | Isopentenyl transferases and uses thereof | 中国科学院分子植物科学卓越创新中心 | 2022-09-27 | — | — | CN | claimed |
| CN-113322045-B | Polythiol modified polyurethane-polythiourethane bonding material | 北京大学 | 2022-08-26 | — | — | CN | claimed |
| US-20250197337-A1 | CONVERSION OF TRIACETIC ACID LACTONE TO POTASSIUM SORBATE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025128424-A1 | CONVERSION OF TRIACETIC ACID LACTONE TO POTASSIUM SORBATE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025043213-A3 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119912730-A | High-strength high-toughness cellulose-based bioplastic, preparation method and application | 江南大学 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025043213-A2 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2025043213-A2 | THERAPEUTIC COMPOUNDS AND METHODS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-119464141-A | Culture medium for rapidly culturing psychrophilic bacteria in cow milk and preparation method thereof | 上海市农产品质量安全中心 | 2025-02-18 | — | — | CN | disclosed |
| US-20250037787-A1 | CONCENTRATION BOUNDS IN LARGE NETWORKS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-01-30 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-0873317-B1 | PYRIMIDIN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2001-04-11 | — | — | EP | disclosed |
| EP-0873317-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| US-5688798-A | PSYCHOTIC ILLNESS SUCH AS SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997013759-A1 | PYRIMIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | KDM4E 1932/4885ALDH1A1 2708/4885HPGD 2630/4885 |
| US-20250197337-A1 | CONVERSION OF TRIACETIC ACID LACTONE TO POTASSIUM SORBATE | STS, BPHL, HPD | KDM4E 1235/4885ALDH1A1 731/4885HPGD 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.